Our People

Meet The Team

Orthocell has attracted world-leading experts in medical research, clinical practice, and commercialization. Orthocell’s Chief Executive Officer and Chief Scientific Officer both have unique experience in the regenerative medicine industry, having been responsible for securing one of the first cell therapy products approved for the repair of cartilage in Australia and having led the sale of one of Australia’s first regenerative medical companies. The Board also features several experienced directors, including a world expert in orthopedics, as well as directors with track records in developing and gaining FDA approval and CE marking for products in the lifescience and healthcare industries. The directors have also successfully sold Australian companies within the healthcare industry to US-based acquirers.

Board of Directors

Stewart Washer_350x220

Dr Stewart James Washer

Chairman

Stewart has 20 years of CEO and Board experience in medical technology, biotech and agrifood companies. He is currently the Chairman of Cynata Therapeutics Ltd (ASX:CYP), Chairman of Minomic International Ltd and Investment Director of Bioscience Managers.

Previously Stewart was the CEO of Calzada Ltd (ASX:CZD), founding CEO of Phylogica Ltd (ASX:PYC) and CEO of Celentis, where he managed the commercialization of intellectual property from AgResearch in New Zealand with 650 scientists and $130m revenues. Stewart was Chairman of iSonea Ltd (ASX:ISN), Resonance Health Ltd (ASX:RHT) and Hatchtech Pty Ltd, a Director of iCeutica Pty Ltd, Immuron Ltd (ASX:IMC) and AusBiotech Ltd. He was also a Senator with Murdoch University.

Paul Anderson_350x220

Mr Paul Anderson

Chief Executive Officer and Managing Director

Paul has over 20 years’ experience in the medical device and cellular therapeutic fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. This encompasses applying the regulatory framework to the product, rebating pathways, marketing, sales, developing key option leader relationships, strategic and financial planning. Paul has a strong track record with his previous board position with Verigen Australia Pty Ltd, a human cell therapies company.

Lars Lidgren Headshot 700x400

Professor Lars Lidgren

Board Member

M.D., Ph.D. Professor in Orthopedics at the University Hospital of Lund. Professor Lidgren leads a productive regenerative medicine research group at the University Hospital of Lund. The hospital is a member of the ISOC group of worldwide leading hospitals and Professor Lidgren is an honorary member and past president of several major societies. He initiated the worldwide Bone and Joint Decade 2000-2010 and is a successful serial entrepreneur who founded the companies Scandimed (Biomet), Bone Support, AMeC and GWS in Sweden.

Leslie Wise New

Ms Leslie Wise

Board Member

Leslie has extensive experience working for both medical device and pharmaceutical companies, including Bristol Myers-Squib, Sanofi, Biomet Orthopedics and AngioDynamics. More recently, Ms Wise has developed expertise in reimbursement, value evidence generation, clinical research strategy and frontline regulatory and payer experience.

Leslie regularly engages with leading experts in health technology assessment, health economics and is at the forefront of developing policies that support greater access for medical technologies. In recognition of her expertise, Leslie was re-appointed to the Medicare Evidence Development Coverage and Advisory Committee (MEDCAC) for 2018-2020. She also partnered with Advamed to facilitate the MedTech Value Summit inaugural event in Minneapolis in 2019.

Matthew Callahan_350x220

Mr Matthew Callahan

Board Member

Matthew is an experienced life sciences executive based in Philadelphia. He is the founding CEO or Executive Director of a number of pharmaceutical and health tech companies including iCeutica Inc, Churchill Pharma Inc. Dimerix Biosciences, Emerald Clinics and Orthocell.

He has led the development of four products that have received FDA approval and he has more than 25 years legal, IP and investment management experience.

Mr Callahan has worked as an investment director for two venture capital firms investing in lifesciences, technology and other sectors, and was general manager of Australian listed technology and licensing company ipernica (now Nearmap ASX:NEA), where he was responsible for the licensing programs that generated more than $120M in revenue.

Professor Qi Xiao Zhou_NEW_700x440

Mr Qi Xiao Zhou

Board Member

Mr Zhou has 15 years’ experience within China as a senior business manager and executive. He has been General Manager of Shenzhen Lightning Digital Technology Co Ltd since 2001, focused on the manufacture and distribution of Semiconductor/Integrated Circuit technology.

Mr Zhou has experience within the public markets in Hong Kong, China and Taiwan and brings to the Board a wealth of business management and business development experience within the Asian regions. In particular Mr Zhou has broad connections and experience in the licensing of technologies into China and licensing into the Asian region.

Executive Management

Paul Anderson_350x220

Mr Paul Anderson

Chief Executive Officer and Managing Director

Paul has over 20 years’ experience in the medical device and cellular therapeutic fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. This encompasses applying the regulatory framework to the product, rebating pathways, marketing, sales, developing key option leader relationships, strategic and financial planning. Paul has a strong track record with his previous board position with Verigen Australia Pty Ltd, a human cell therapies company.

Professor Qi Xiao Zhou_350x220

Professor Ming Hao Zheng

Chief Scientific Officer

Professor Zheng has 15 years’ experience within China as a senior business manager and executive. This includes experience within the public markets in Hong Kong, China and Taiwan.

Professor Zheng is inventor of Orthocell’s technology and brings a strong track record of innovation to the company. He completed his PhD in 1993 and Doctor of Medicine (DM) in 1998 at the University of Western Australia and is a Fellow of the Royal College of Pathologists.

Currently, Professor Zheng is the Director of Research in the Department of Orthopaedic Surgery at The University of Western Australia. His research focus involves using cutting-edge cellular and molecular biology technique to discover new ways to treat osteoporosis, osteoarthritis and tendon injuries.

Nic Telford_350x220

Ms Nicole Telford

Chief Financial Officer

Nicole is a chartered accountant with over 14 years’ commercial experience in financial controller/group accountant roles. Nicole achieved her professional qualifications while employed at Arthur Andersen in the audit division, providing her with a broad range of experience. She has commercial experience in financial and management reporting, office administration and staff management.

Alex McHenry_350x220

Mr Alex McHenry

Chief Operating Officer

Alex has over 17 years of experience in corporate advisory and management consulting, with a particular focus on the execution of corporate strategy, capital raising and business transformation initiatives in the biotechnology and resources industry. Alex started his career with Arthur Anderson, assisting clients with business transformation strategy and implementation of operational improvement programs. Prior to joining Orthocell, Alex worked as a corporate consultant, working with his clients in the execution and financing of asset acquisitions and in the management of development programs in the biotechnology and mining sectors in Australia and SE Asia.

Work With Us

We are proud to be working in partnership with some of the world’s most respected medical researchers, clinicians, academic institutions and sector specialists. If you would like to find out about working with us, please contact our team.